1. Hashemi, Mohammad, Sarabandi, Sahel, Karami, Shima, Ghavami, Saeid, Łos, Marek J. 2019. LMO1 polymorphisms and the risk of neuroblastoma: Assessment of meta-analysis of case-control studies. In Journal of cellular and molecular medicine, 24, 1160-1168. doi:10.1111/jcmm.14836. https://pubmed.ncbi.nlm.nih.gov/31830377/
2. Gao, Lei, Wu, Jia, Wang, Hai, Peng, Yuping, Li, Yaomin. 2022. LMO1 Plays an Oncogenic Role in Human Glioma Associated With NF-kB Pathway. In Frontiers in oncology, 12, 770299. doi:10.3389/fonc.2022.770299. https://pubmed.ncbi.nlm.nih.gov/35280742/
3. Li, Guoyuan, Jia, Wei, Yin, Zijun, He, Jing, Fu, Wen. 2019. LMO1 Super-Enhancer rs2168101 G>T Polymorphism Reduces Wilms Tumor Risk. In Journal of Cancer, 10, 1808-1813. doi:10.7150/jca.29842. https://pubmed.ncbi.nlm.nih.gov/31205537/
4. Zhu, Shizhen, Zhang, Xiaoling, Weichert-Leahey, Nina, Maris, John M, Look, A Thomas. 2017. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. In Cancer cell, 32, 310-323.e5. doi:10.1016/j.ccell.2017.08.002. https://pubmed.ncbi.nlm.nih.gov/28867147/
5. Liu, Zhihui, Thiele, Carol J. . When LMO1 Meets MYCN, Neuroblastoma Is Metastatic. In Cancer cell, 32, 273-275. doi:10.1016/j.ccell.2017.08.014. https://pubmed.ncbi.nlm.nih.gov/28898690/
6. Du, Liqin, Zhao, Zhenze, Suraokar, Milind, Wistuba, Ignacio, Pertsemlidis, Alexander. 2018. LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. In Oncotarget, 9, 29601-29618. doi:10.18632/oncotarget.25642. https://pubmed.ncbi.nlm.nih.gov/30038707/